Sagem, B-Temia Sign Partnership Agreement in New Generation Exoskeletons

11.11.2015 Joint Ventures
Sagem, B-Temia Sign Partnership Agreement in New Generation Exoskeletons

Sagem, B-Temia Sign Partnership Agreement in New Generation Exoskeletons

Facebook icon
Twitter icon
LinkedIn icon
Google icon
e-mail icon

Canadian company B-Temia, Inc. and French company Sagem (Safran) announced the signature of a technological and business development agreement concerning a new generation of exoskeletons for industrial and military applications.

Exoskeletons are bio-mechanical and electronic structures worn on the body to assist and enhance people's movements, or to restore mobility.

According to the terms of this agreement, Sagem and B-Temia will jointly develop and market new-generation exoskeletons. Sagem will contribute its long experience in the integration of complex systems, its innovative actuators and stabilization technologies.

BTemia, an exoskeleton technology leader, will contribute its experience in human robotics and artificial intelligence, based on its proprietary "Dermoskeleton™" technology, already in production for the healthcare sector.

“B-Temia is very proud of this partnership with Sagem, focused on the development and production of our dermoskeleton products. This agreement confirms our company's technology leadership business value, and the credibility of our work addressing increased human mobility needs in both industrial and defense applications,” said Stéphane Bédard, President and CEO of B-Temia.

Martin Sion, Chief Executive Officer of Sagem, added: “Our collaboration with B-Temia will enable us to sustain new R&D work on exoskeletons. For Sagem, this is a very promising technology for industrial and military applications. In particular, our collaboration spotlights the dynamic mindset that Sagem seeks to deploy in the application of innovative dual technologies in conjunction with both startups and major corporations.”

B-Temia Inc. is a private medical technology company that develops and markets products in the growing market for human augmentation systems. B-Temia has two wholly-owned subsidiaries, B-Temia Health Inc. and B-Temia Military Inc. B-Temia has developed a proprietary technology called a Dermoskeleton™, giving users a motorized mechanical support to restore, maintain or augment mobility.

Sagem, a Safran high-tech company, holds world leadership positions in optronics, avionics, electronics and critical software for both civil and military markets. Sagem is the # 1 company in Europe and # 3 worldwide for inertial navigation systems (INS) used in air, land and naval applications.

Sagem is also the world leader in helicopter flight controls and the European leader in optronics and tactical UAV systems. Operating across the globe through the Safran international network, Sagem and its subsidiaries employ 7,600 people in Europe, Asia-Pacific, North America and South America.



Latest events

Latest Issues